Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer

Journal of Clinical Oncology

Volumn 20, Issue 23, 2002, Pages 4517-4522

  Lipshultz, Steven E ^a,b,c,d   Lipsitz, Stuart R ^a,b,c   Sallan, Stephen E ^a,b,c   Simbre II, Valeriano C ^a,b,c   Shaikh, Seema L ^a,b,c   Mone, Suzanne M ^a,b,c   Gelber, Richard D ^a,b,c   Colan, Steven D ^a,b,c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL;

ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART AFTERLOAD; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE MASS; HEART TRANSPLANTATION; HEART VENTRICLE HYPERTROPHY; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHILD; DEATH, SUDDEN, CARDIAC; DIASTOLE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; ENALAPRIL; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; NEOPLASMS; RETROSPECTIVE STUDIES; RISK; SURVIVORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0036895164     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.12.102     Document Type: Article

References (29)

1. Office of Cancer Survivorship, National Cancer Institute Workshop on Long-Term Follow-Up Care Programs for Survivors of Pediatric Cancer, Niagara-on-the-Lake, Ontario, Canada, June 25, 2002
2. Lipshultz SE, Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815, 1991
3. Lipshultz SE, Lipsitz SR, Mone SM, et al: Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743, 1995
4. Grenier MA, Lipshultz SE: Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25:72-85, 1998 (suppl 10)
5. Giantris A, Abdurrahman L, Hinkle A, et al: Anthracycline-induced cardiotoxicity. Crit Rev Oncol Hematol 27:53-68, 1998
6. Nysom K, Colan SD, Lipshultz SE: Late cardiotoxicity following anthracycline therapy for childhood cancer. Prog Pediatr Cardiol 8:121-138, 1998
7. Lipshultz SE: Ventricular dysfunction clinical research in infants, children and adolescents. Prog Pediatr Cardiol 12:1-28, 2000
8. Mertens AC, Yasui Y, Neglia JP, et al: Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study. J Clin Oncol 19:3163-3172, 2001
9. Green DM, Hyland A, Chung CS, et al: Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. J Clin Oncol 17:3207-3215, 1999
10. Grenier MA, Fioravanti J, Truesdell SC, et al: Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescence: A review. Prog Pediatr Cardiol 12:91-111, 2000
11. Beinlich CJ, Rissinger CJ, Vitkauskas KJ, et al: Role of bradykinin in the antihypertrophic effects of enalapril in the newborn pig heart. Mol Cell Biochem 164:77-83, 1996
12. Wamboldt RB, Henning SL, English DR, et al: Regression of cardiac hypertrophy normalizes glucose metabolism and left ventricular function during reperfusion. J Mol Cell Cardiol 29:939-948, 1997
13. Cichoka E, Kawalec W, Januszewics P, et al: The effect of ACE inhibition on left ventricular function and structure in hypertensive adolescents. Pediatria Polska 70:145-151, 1995
14. Colan SD, Parness IA, Spevak PJ, et al: Developmental modulation of myocardial mechanics: Age and growth-related alterations in afterload and contractility. J Am Coll Cardiol 19:619-629, 1992
15. Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 57:450-458, 1986
16. Lipshultz SE, Easley K, Orav EJ, et al: The reliability of multicenter pediatric echocardiographic measurements of left ventricular structure and function. Circulation 104:310-316, 2001
17. Gullestad LA, Aukrust P, Ueland T, et al: Effects of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 34:2061-2067, 1999
18. Simbre VC II, Adams MJ, Despande SS, et al: Cardiomyopathy caused by antineoplastic therapies. Curr Treat Options Cardiovasc Med 3:493-505, 2001
19. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685-691, 1992
20. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial - The SAVE Investigators. N Engl J Med 327:669-677, 1992
21. Cohn JN, Johnson G, Ziesche S, et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303-310, 1991
22. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302, 1991
23. Dixon IMC, Reid NL, Ju H: Angiotensin II and TGF beta in the development of cardiac fibrosis, myocyte hypertrophy and heart failure. Heart Failure Rev 2:107-116, 1997
24. Kichuk MR, Zhang X, Oz M, et al: Angiotensin-converting enzyme inhibitors promote nitric oxide production in coronary microvessels from failing explanted human hearts. Am J Cardiol 70:137A-142A, 1997
25. Loirat C, Azznot A, Pillion G, et al: Sequential echocardiographic study prior and during antihypertensive therapy in children with severe hypertension. Clin Exp Hypertens A8:805-810, 1986
26. Liebermann E: Pediatric hypertension: Clinical perspective. Mayo Clin Proc 69:1098-1107, 1994
27. Jensen BV, Nielsen SL, Skovsgaard T: Treatment with angiotensinconverting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 347:297-299, 1996
28. Silber JH, Cnaan A, Clark BJ, et al: Design and Baseline Characteristics for the ACE Inhibitor After Anthracycline (AAA) Study of Cardiac
29. dysfunction in long-term pediatric cancer survivors. Am Heart J 142:577-585, 2001